A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Double-blind, Placebo-controlled study to confirm the superiority of MR13A9 to placebo, and
followed by extension, open-label treatment to confirm long-term safety of MA13A9 in
hemodialysis patients with pruritus.